1. As of noon trading, Pfizer ( PFE) is down $0.24 (-0.8%) to $30.70 on light volume. Thus far, 7.9 million shares of Pfizer exchanged hands as compared to its average daily volume of 25.1 million shares. The stock has ranged in price between $30.60-$31.12 after having opened the day at $31.08 as compared to the previous trading day's close of $30.95. Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $199.2 billion and is part of the health care sector. The company has a P/E ratio of 20.4, above the S&P 500 P/E ratio of 17.7. Shares are up 1.0% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold. TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).